DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Drawings
The drawings were received on 5//21/2026. These drawings are acceptable.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 6 and 13 of U.S. Patent No. 11,744,694. Although the claims at issue are not identical, they are not patentably distinct from each other because all of the limitations of the claims of this application are anticipated by the claims of the
In regards to claim 1: Claim 6 of the ‘694 patent recites the limitation (d)(ii) that proximal direction withdrawal of the stent conveyance tube is effective to disengage the proximally withdrawable locking mechanism. Limitations (a) and (b) of claim 1 of this application are anticipated by claim 1 of the ‘694 patent. Limitation (c) requiring a pushing tube and limitation (d) requiring a proximally withdrawable locking mechanism are recited in claim 5, from which claim 6 depends. Claim 5 states that the proximally withdrawable locking mechanism engages the stent with the pushing tube, which is stated in limitation (d) of claim 1 of this application. Although Claim 5 of ‘694 states that the locking mechanism is “effective to maintain a position of the stent relative to the stent-conveyance tube when the assembly is advanced along the guidewire in the stent-advancement configuration” is considered to anticipate the language “constrain distal movement of the stent relative to the pushing tube” in limitation (d) of this application, since maintaining the position of the stent requires that distal movement be constrained. It is considered obvious to state a certain direction of movement in which the stent is constrained, where the patent states that the position of the stent is maintained relative to the stent-conveyance tube on which it is mounted.
In regards to claim 1: Claim 13 of the ‘694 patent recites the limitation (d)(ii) that proximal direction withdrawal of the stent conveyance tube is effective to disengage the proximally withdrawable locking mechanism. Limitations (a) and (b) of claim 1 of this application are anticipated by claim 9 of the ‘694 patent. Limitation (c) requiring a pushing tube and limitation (d) requiring a proximally withdrawable locking mechanism are recited in claim 12, from which claim 13 depends. Claim 12 states that the proximally withdrawable locking mechanism engages the stent with the pushing tube, which is stated in limitation (d) of claim 1 of this application. Although claim 12 of ‘694 states that the locking mechanism is “effective to maintain a position of the stent relative to the stent-conveyance tube when the assembly is advanced along the guidewire in the stent-advancement configuration” is considered to anticipate the language “constrain distal movement of the stent relative to the pushing tube” in limitation (d) of this application, since maintaining the position of the stent requires that distal movement be constrained. It is considered obvious to state a certain direction of movement in which the stent is constrained, where the patent states that the position of the stent is maintained relative to the stent-conveyance tube on which it is mounted.
Allowable Subject Matter
Claims 12-14, 17-19 and 21-23 are allowed.
Claims 2-11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
The following is an examiner’s statement of reasons for allowance:
Regarding claim 1: Prior art discloses stent-deployment assemblies having a guidewire that is configured to breach a laterally breachable portion of a guidewire retaining segment. USPAP 2019/0000652 (Einav et al.) discloses a stent deployment assembly have a stent (52) mounted on a stent conveyance tube (22) that has a guidewire retaining segment (122) (see region 55 in Figure 2), wherein proximal-direction withdrawal of the stent-conveyance tube is effective to (i) cause the guidewire (12) to breach the laterally-breachable portion (via slit 28) of the guidewire-retaining segment so as to decouple the guidewire from the tube without manipulation of the guidewire (see Figure 3A-3C; [0161-0175]). Einav fails to include a pushing tube proximal to the stent, with a proximally-withdrawable locking mechanism engaging the stent with the pushing tube, as a second stent (54) is positioned proximal to the first stent (52).
Prior art discloses the concept of a proximally withdrawable locking mechanism that engages a proximal end of a stent with a pushing tube, such that proximal movement of an internal stent conveyance tube disengages the locking mechanism. For example, USPAP 2005/0085891 (Goto) discloses a stent delivery device in Figures 1A-D with a stent conveyance tube (11), a stent (14) mounted on the stent-conveyance tube, a pushing shaft (15) positioned proximal to the stent, and a locking mechanism in the form of a ball (21) and detent (17), wherein proximal movement of the stent-conveyance tube is effective to disengage the locking mechanism [0051].
Further in regards to claim 1: Prior art fails to disclose or render obvious a stent deployment assembly wherein when movement of the stent is externally constrained, a proximal a proximal-direction withdrawal of the stent-conveyance tube is effective to (i) cause the guidewire to breach the laterally-breachable portion of the guidewire-retaining segment so as to decouple the guidewire from the tube without manipulation of the guidewire, and (ii) disengage the proximally- withdrawable locking mechanism. In other words, proximal movement of the stent conveyance tube causes the guidewire release from the guidewire retaining segment and the locking mechanism to release the stent from the pushing tube.
Regarding claim 12: Aoba discloses the first locking member (40) is connected to and moves along with the slider (62), which moves relatively to the stent-conveyance tube (10) (see Figures 7-8; col 9, lines 1-10). Aoba fails to disclose or render obvious the first locking member is integrally formed with the stent-conveyance tube or fixedly attached to the stent conveyance tube, as such a modification would render the device inoperable for its intended purpose.
Regarding claim 18: the prior art fails to disclose or render obvious wherein when movement of the stent is externally constrained, a proximal-direction withdrawal of the stent-conveyance tube is effective to cause the second locking member (30) to no longer be constrained by the first locking member (40).
Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH WEBB ALEMAN whose telephone number is (571)272-5749. The examiner can normally be reached M, Tu, Th, Fr 9am - 3pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SARAH W ALEMAN/Primary Examiner, Art Unit 3774